Browsing by Author "Stojiljkovic, Tanja (55765488000)"

Purpose: To present the experience of our center with cytoreductive surgery (CRS) and hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of various potentially resectable chemo-sensitive pleural malignancies, primary and metastatic, limited to the unilateral thoracic inlet, as well as to address potential extension of indications for this procedure. Methods: This retrospective study included patients treated with CRS+HITHOC at the Institute for Oncology and Radiology of Serbia from January 2018 to August 2021. Indications for CRS+HITHOC were: (1) potentially resectable chemo-sensitive primary or residual/recurrent thoracic malignancy, with no signs of disease outside the thoracic cavity, and (2) miscellaneous metastatic disease limited to the unilateral thoracic inlet. All HITHOC procedures were performed with 90 min cisplatin perfusion (100 mg/m2 in 1000 ml of 5%-glucose gradually heated to 42°C). Results: A total of 7 patients were included in this study, with a mean age of 41.43 ± 19.25 years (range: 16-62). R0 resections were achieved in all patients. All CRS+HITHOC procedures were uneventful, with no metabolic or hemodynamic disorders intraoperatively. Average follow-up was 25.71±9.83 months (range: 14-40). Overall survival rate was 100%. There were no local relapses in the thoracic cavity. Conclusions: This study showed that CRS+HITHOC procedure might be successfully used not only for current indications, but also for a limited metastatic disease of a primary outside the thoracic cavity. Larger, multicentric studies might provide more data on oncological outcomes and cost-effectiveness of this procedure. © 2021 Zerbinis Publications. All rights reserved.

Purpose: To present the experience of our center with cytoreductive surgery (CRS) and hyperthermic intrathoracic chemotherapy (HITHOC) in the treatment of various potentially resectable chemo-sensitive pleural malignancies, primary and metastatic, limited to the unilateral thoracic inlet, as well as to address potential extension of indications for this procedure. Methods: This retrospective study included patients treated with CRS+HITHOC at the Institute for Oncology and Radiology of Serbia from January 2018 to August 2021. Indications for CRS+HITHOC were: (1) potentially resectable chemo-sensitive primary or residual/recurrent thoracic malignancy, with no signs of disease outside the thoracic cavity, and (2) miscellaneous metastatic disease limited to the unilateral thoracic inlet. All HITHOC procedures were performed with 90 min cisplatin perfusion (100 mg/m2 in 1000 ml of 5%-glucose gradually heated to 42°C). Results: A total of 7 patients were included in this study, with a mean age of 41.43 ± 19.25 years (range: 16-62). R0 resections were achieved in all patients. All CRS+HITHOC procedures were uneventful, with no metabolic or hemodynamic disorders intraoperatively. Average follow-up was 25.71±9.83 months (range: 14-40). Overall survival rate was 100%. There were no local relapses in the thoracic cavity. Conclusions: This study showed that CRS+HITHOC procedure might be successfully used not only for current indications, but also for a limited metastatic disease of a primary outside the thoracic cavity. Larger, multicentric studies might provide more data on oncological outcomes and cost-effectiveness of this procedure. © 2021 Zerbinis Publications. All rights reserved.

Purpose: To analyze the correlation of primary tumor (PT) pathological characteristics (size, stage, type and grade) and the extent of initial surgical treatment of non small cell lung cancer (NSCLC) with the incidence and time to local recurrence (LR) and disease-free survival (DFS), as well as to determine in what way these parameters and LR localizations affect the possibility for surgical retreatment. Methods: The research was conducted on 114 patients with NSCLC and LR that had initial surgery in two reference institutes in Serbia from January 2002 to December 2010. PT size and disease stage were defined according to the revised 2004 WHO classification. PTs were grouped by size into 3 categories. Due to great diversity, surgical procedures were sorted into 6 operation types. Standard statistical methods and tests were used for data analysis. Results: Statistical analyses showed significant difference in DFS and LR reoperability that were related to PT size, disease stage and the extent of initial surgery. LR localization on the chest wall was favorable for secondary surgery due to LR. Conclusions: Squamous cell lung carcinoma relapses locally more frequently than other lung tumor types, and the commonest LR site is the chest wall. This localization provides high possibility for surgical retreatment. Adequate staging, proper indications for surgical treatment and quality surgery provide longer DFS in patients with NSCLC. All these suggest that the surgeon may be considered as the most significant factor of prognosis.

Purpose: To analyze the correlation of primary tumor (PT) pathological characteristics (size, stage, type and grade) and the extent of initial surgical treatment of non small cell lung cancer (NSCLC) with the incidence and time to local recurrence (LR) and disease-free survival (DFS), as well as to determine in what way these parameters and LR localizations affect the possibility for surgical retreatment. Methods: The research was conducted on 114 patients with NSCLC and LR that had initial surgery in two reference institutes in Serbia from January 2002 to December 2010. PT size and disease stage were defined according to the revised 2004 WHO classification. PTs were grouped by size into 3 categories. Due to great diversity, surgical procedures were sorted into 6 operation types. Standard statistical methods and tests were used for data analysis. Results: Statistical analyses showed significant difference in DFS and LR reoperability that were related to PT size, disease stage and the extent of initial surgery. LR localization on the chest wall was favorable for secondary surgery due to LR. Conclusions: Squamous cell lung carcinoma relapses locally more frequently than other lung tumor types, and the commonest LR site is the chest wall. This localization provides high possibility for surgical retreatment. Adequate staging, proper indications for surgical treatment and quality surgery provide longer DFS in patients with NSCLC. All these suggest that the surgeon may be considered as the most significant factor of prognosis.